Founded in late 2017, Temisis is a biotechnology company focused on the discovery and development of novel small molecule compounds to treat inflammatory diseases with high unmet needs. TEM1657, our lead program has showed great efficacy in pre-clinical studies, both orally and topically, to relieve psoriasis symptoms without the side effects associated with existing treatments. TEM1657 unique efficacy and safety profile is explained by its first-in-class MoA, currently under investigation.